# FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-31 08:29 UTC · Category: Business · Sources: 9 · Current Velocity: 7.5

## Executive Summary
9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

## Intelligence Brief
"FDA Panel Votes In Favor of Replimune’s Melanoma Treatment" is generating significant coverage in the Business category, with 10 articles from 9 distinct sources tracked by Newsylist so far.


Outlets currently covering the story include biopharmadive.com, FirstWord Pharma, Barron's and qz.com. Newsylist measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### Why is "FDA Panel Votes In Favor of Replimune’s Melanoma Treatment" trending?
Because 9 independent news sources published 10 articles about it in a short window — a coverage burst Newsylist classifies as a trend.

### How does Newsylist measure this trend?
Newsylist scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

### Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

## Key People, Organizations & Locations
FDA, US FDA, FDA Panel Votes In Favor, Melanoma Treatment, Why Is REPL Stock Soaring, After Hours Today, Replimune, This Biotech Stock Is Soaring, After Key FDA Panel Vote, Skin Cancer Treatment

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| biopharmadive.com | Replimune melanoma drug wins support of FDA panel | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxPY2t6SVpvYlhMQUdTbE5qcXJrZlU2WnFSU21fdklkRFVBQUYtRFJCbnRpaVltWEVnWkY2YlBXOF92VHUwUmhkSFpOazVfWktJNFpkTjBrUEYxdmFzRFZBUGhiYVlmdzNDVUl4eExsbC1qVWx2NzZUMUVlOTBXTkp1d1RIT2NLTGh6Z2l3Vi1OZTdmU1p3RklOdms1TnY1dW8?oc=5) |
| FirstWord Pharma | Replimune's oncolytic immunotherapy clears FDA panel despite trial flaws | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA0R0k3X08xQnFhdGpJTWxyR1JKdm1qbnRSTDNYOHAyekQ0M2hkaEViZG1DelE5RFZuNW9hN1Q0VmgyVm9adFVOTkZBaElqbDZlY3Rr?oc=5) |
| Barron's | This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxOS2ZnUkhSRDk0OHRSc0g5WlhaMGFLYTNYWEh3Z0xSTnRrZEFlQjNSTFNxb3FTR0RoYXJFU2dVVG13MFo2c1MzeFhfU01LSnZ0UXgwYXd1YTltMzBuU0xaS2gzU0pPQkhGalBGck16QmlCWjRCVWNNV2twT080TWo5V2o3eU1pdw?oc=5) |
| qz.com | FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMid0FVX3lxTE41REdsNjFBWDBzREdfUFVLQUlQUy1obW5tcUE2WFF5Vk9Md3g3T2I3c0hEdDZBZnpDSmxSTWhaaVlYY1EwMmFKU2FiLXBHQTd5emNyNGlPYy1wQmtoLXkxR05na2VNUFA4WFp1eU41THRKY1NXRi1R?oc=5) |
| Yahoo Finance | REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxORW5mbUc1cEtLOWM1UUthNFo2ZmJTNGtMVTZ5SjFjY1Y4enl5ZDFlWkgyNEtueHRaeTNVSVczc2thOFpSeXY3TW04NEs0bzRpdThzalJBNlE4NW15VllmbGhHN3Qtc29zTVNkUl96Q0ZxOUxxMExlS29ZanJyUWRoNEYwT3RnSVM3dHFzRGpGbEI?oc=5) |
| STAT | FDA expert committee votes in favor of Replimune’s melanoma treatment | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxNdHg3eTBGQ1BMUXl2ZlZtSW1WZVl1eVQ0emNNTndZWS1TelQwOW5oS2h1U3pYVXE2NTBoeGdjbm5tdjFSUmRSOXBaRFVmcEo3QnVrMlZwXzRIZS12SFQ4ZXN0RGZxamM5WGtCX0lLZ2VKRlo1b3I3U1dWTGFTcDRJclp3bHJUekZIWHlJZlpza3ZJYTg2ZzJMaQ?oc=5) |
| Fierce Biotech | Replimune’s twice-rejected melanoma drug prevails in FDA adcomm | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxQekdjdnZVWVpRYnRCdWo0UjF2elFDbGRlTVh3TG5pb2xlcmU3QXpUQW5mRk1RemQ5UW9RMEM0bng0ajZoQlBpQ21MckZkU3lzaWdSS29RWFRScl9DaGhkWW14VENhLURUWU5nNUR2eGZKbUZlVWVtM2lIVllEaEZwYVYyWkVKcUNaUDNMVWt4M0tMcGZkNU4tdUtkbTdodw?oc=5) |
| Yahoo Finance | Why Is REPL Stock Soaring 127% After Hours Today? | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxQcWlsWmhvcC05U2h4WlA0enJqbjFTUnhHS2l2R3Utc1NMaE5BYUc3OU1fWjJYUGpNdU1vMGx5THpYUFdubE03TlkzaWgwcnBUeVRzLW5fU0tudGh4NE1hZjBGekZLLXpxUjhjQkk2TDhQLXJUV2hDYmhselpiS0Y2aWN3NWkwa1VnbmN4R3UtTWQ?oc=5) |
| Reuters | US FDA advisers back Replimune skin cancer drug trial data | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxPaWRkMjZ0enVTN1Y5ZzlPRjlMUUFCbWZjUmpvb0VILXZKaTdid2hHbVl2NGl5N3FXNlZrNGF6UXpjaFM0Vk5ZUUp6ejZ0Sm14NXNvWmZBd1A1RXVoQVJqc01XNDdGX0h0LWpRMXNhUUoxRmNGemRCZUVQcFZvYXZ4UU5CYlc5dkVtZHlnZ3JjNDYtSnMtSmY2ZUhYZXRpamx6XzZDblpIOTVxdjlETmxncGVxVG5FcFF4LUhXXzhNRHhVNmdyY3pR?oc=5) |
| wsj.com | FDA Panel Votes In Favor of Replimune’s Melanoma Treatment | 2026-07-30 21:27 | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxNdmFCTEFTbkkzQzJqdHRSSE1tMTUzclF3V0xmZG5XSS1VUHVOOXNEVEtlbHZORXNhX3BqSXRuOC1zN1JFMWRSRjZKVEhiQnBUcFdIT3NxeE0yLWZUQ0NvY0c1VEludHRYcTZET2FjYzdMam1UUlhYdjNER0tCVGxRSUdWZUdpU3FydVJZdkxCQ1hPRGNaOEZFWExUazlieWtseFE?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-31/fda-panel-votes-in-favor-of-replimune-s-melanoma-treatment*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*